These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29241838)

  • 1. Telomerase level increase is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: Secondary outcome analysis of the OFFER randomized clinical trial.
    Pawełczyk T; Grancow-Grabka M; Trafalska E; Szemraj J; Żurner N; Pawełczyk A
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Apr; 83():142-148. PubMed ID: 29241838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An increase in plasma brain derived neurotrophic factor levels is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: secondary outcome analysis of the OFFER randomized clinical trial.
    Pawełczyk T; Grancow-Grabka M; Trafalska E; Szemraj J; Żurner N; Pawełczyk A
    Psychopharmacology (Berl); 2019 Sep; 236(9):2811-2822. PubMed ID: 31098654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia.
    Pawełczyk T; Grancow-Grabka M; Kotlicka-Antczak M; Trafalska E; Pawełczyk A
    J Psychiatr Res; 2016 Feb; 73():34-44. PubMed ID: 26679763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods.
    Pawełczyk T; Grancow M; Kotlicka-Antczak M; Trafalska E; Gębski P; Szemraj J; Żurner N; Pawełczyk A
    BMC Psychiatry; 2015 May; 15():97. PubMed ID: 25934131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative stress reduction related to the efficacy of n-3 polyunsaturated fatty acids in first episode schizophrenia: Secondary outcome analysis of the OFFER randomized trial.
    Pawełczyk T; Grancow-Grabka M; Trafalska E; Szemraj J; Pawełczyk A
    Prostaglandins Leukot Essent Fatty Acids; 2017 Jun; 121():7-13. PubMed ID: 28651701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omega-3 fatty acid supplementation may prevent loss of gray matter thickness in the left parieto-occipital cortex in first episode schizophrenia: A secondary outcome analysis of the OFFER randomized controlled study.
    Pawełczyk T; Piątkowska-Janko E; Bogorodzki P; Gębski P; Grancow-Grabka M; Trafalska E; Żurner N; Pawełczyk A
    Schizophr Res; 2018 May; 195():168-175. PubMed ID: 29079060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omega-3 fatty acids reduce cardiometabolic risk in first-episode schizophrenia patients treated with antipsychotics: Findings from the OFFER randomized controlled study.
    Pawełczyk T; Grancow-Grabka M; Żurner N; Pawełczyk A
    Schizophr Res; 2021 Apr; 230():61-68. PubMed ID: 33684737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia.
    Bentsen H; Osnes K; Refsum H; Solberg DK; Bøhmer T
    Transl Psychiatry; 2013 Dec; 3(12):e335. PubMed ID: 24346133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
    Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
    Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.
    Amminger GP; Schäfer MR; Papageorgiou K; Klier CM; Cotton SM; Harrigan SM; Mackinnon A; McGorry PD; Berger GE
    Arch Gen Psychiatry; 2010 Feb; 67(2):146-54. PubMed ID: 20124114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia.
    Emsley R; Chiliza B; Asmal L; du Plessis S; Phahladira L; van Niekerk E; van Rensburg SJ; Harvey BH
    Schizophr Res; 2014 Sep; 158(1-3):230-5. PubMed ID: 24996507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol.
    Qurashi I; Chaudhry IB; Khoso AB; Farooque S; Lane S; Husain MO; Chu S; Sarginson J; Hamarani M; Naqvi HA; Razzaque B; Minhas FA; Yung AR; Deakin JFW; Husain N
    Trials; 2017 Nov; 18(1):524. PubMed ID: 29121974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, placebo-controlled clinical trial of omega-3 as supplemental treatment in schizophrenia.
    Jamilian H; Solhi H; Jamilian M
    Glob J Health Sci; 2014 Sep; 6(7 Spec No):103-8. PubMed ID: 25363186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: A randomized controlled trial.
    Kiecolt-Glaser JK; Epel ES; Belury MA; Andridge R; Lin J; Glaser R; Malarkey WB; Hwang BS; Blackburn E
    Brain Behav Immun; 2013 Feb; 28():16-24. PubMed ID: 23010452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omega-3 Fatty Acid Supplementation Improves Endothelial Function in Primary Antiphospholipid Syndrome: A Small-Scale Randomized Double-Blind Placebo-Controlled Trial.
    Felau SM; Sales LP; Solis MY; Hayashi AP; Roschel H; Sá-Pinto AL; Andrade DCO; Katayama KY; Irigoyen MC; Consolim-Colombo F; Bonfa E; Gualano B; Benatti FB
    Front Immunol; 2018; 9():336. PubMed ID: 29552010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of omega-3 fatty acid supplementation in schizophrenia: possible mechanisms.
    Hsu MC; Huang YS; Ouyang WC
    Lipids Health Dis; 2020 Jul; 19(1):159. PubMed ID: 32620164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin E and essential polyunsaturated fatty acids supplementation in schizophrenia patients treated with haloperidol.
    Bošković M; Vovk T; Koprivšek J; Plesničar BK; Grabnar I
    Nutr Neurosci; 2016 May; 19(4):156-61. PubMed ID: 25056532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
    Davidson M; Saoud J; Staner C; Noel N; Luthringer E; Werner S; Reilly J; Schaffhauser JY; Rabinowitz J; Weiser M; Luthringer R
    Am J Psychiatry; 2017 Dec; 174(12):1195-1202. PubMed ID: 28750582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of omega-3 fatty acid supplementation on telomere length and telomerase activity: A systematic review of clinical trials.
    da Silva A; Silveira BKS; Hermsdorff HHM; da Silva W; Bressan J
    Prostaglandins Leukot Essent Fatty Acids; 2022 Jun; 181():102451. PubMed ID: 35661999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of marine n-3 polyunsaturated fatty acids on cardiac autonomic and hemodynamic function in patients with psoriatic arthritis: a randomised, double-blind, placebo-controlled trial.
    Kristensen S; Schmidt EB; Schlemmer A; Rasmussen C; Lindgreen E; Johansen MB; Christensen JH
    Lipids Health Dis; 2016 Dec; 15(1):216. PubMed ID: 27955663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.